PE20212067A1 - Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada - Google Patents

Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada

Info

Publication number
PE20212067A1
PE20212067A1 PE2021001372A PE2021001372A PE20212067A1 PE 20212067 A1 PE20212067 A1 PE 20212067A1 PE 2021001372 A PE2021001372 A PE 2021001372A PE 2021001372 A PE2021001372 A PE 2021001372A PE 20212067 A1 PE20212067 A1 PE 20212067A1
Authority
PE
Peru
Prior art keywords
trifluoromethyl
crystalline form
dihydroisoquinolin
carboxamide
pyridin
Prior art date
Application number
PE2021001372A
Other languages
English (en)
Inventor
Carina Leys
Kristof Leonard Kimpe
Robert Michael Geertman
Haojuan Wei
Peng Zhou
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Publication of PE20212067A1 publication Critical patent/PE20212067A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Referido a una forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5- (trifluorometil)-N-[2-(trifluorometil)piridin-4-il]-1H-pirazol-4-carboxamida (Compuesto A) monohidratada, donde la forma cristalina es la Forma III, que produce un patron de difraccion de rayos X de polvo que comprende picos a 16.4, 23.7 y 25.7 grados dos theta ± 0.2 grados dos theta. Tambien se refiere a composiciones farmaceuticas; el proceso de preparacion de la forma cristalina, que comprende el paso de recristalizar el compuesto A; y a su uso en el tratamiento del cancer y enfermedades, sindromes, trastornos o afecciones autoinmunologicos asociados con inhibidores de MALT1.
PE2021001372A 2019-02-22 2020-02-20 Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada PE20212067A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2019075834 2019-02-22
PCT/EP2020/054485 WO2020169736A1 (en) 2019-02-22 2020-02-20 Crystalline form of 1-(1-oxo-1,2-dihydroisoquinolin-5-yl)-5-(trifluoromethyl)-n-(2-(trifluoromethyl)pyridin-4-yl)-1h-pyrazole-4-carboxamide monohydrate

Publications (1)

Publication Number Publication Date
PE20212067A1 true PE20212067A1 (es) 2021-10-26

Family

ID=69723907

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021001372A PE20212067A1 (es) 2019-02-22 2020-02-20 Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada

Country Status (20)

Country Link
US (1) US20220127249A1 (es)
EP (1) EP3927696B1 (es)
JP (1) JP2022523368A (es)
KR (1) KR20210131371A (es)
CN (1) CN113474339A (es)
AU (1) AU2020226723A1 (es)
BR (1) BR112021016400A2 (es)
CA (1) CA3129623A1 (es)
EA (1) EA202192320A1 (es)
EC (1) ECSP21067828A (es)
ES (1) ES2966132T3 (es)
IL (1) IL285675A (es)
JO (1) JOP20210227A1 (es)
MA (1) MA55019A (es)
MX (1) MX2021010133A (es)
PE (1) PE20212067A1 (es)
SG (1) SG11202108909SA (es)
TW (1) TW202045495A (es)
UY (1) UY38592A (es)
WO (1) WO2020169736A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023539729A (ja) 2020-08-21 2023-09-19 ヤンセン ファーマシューティカ エヌ．ベー． Ｍａｌｔ１阻害剤の非晶質形態及びその製剤
JP2024508890A (ja) 2021-03-03 2024-02-28 ヤンセン ファーマシューティカ エヌ．ベー． 治療有効用量のｍａｌｔ１阻害剤ｊｎｊ－６７８５６６３３（１－（１－オキソ－１，２－ジヒドロイソキノリン－５－イル）－５－（トリフルオロメチル）－ｎ－（２－（トリフルオロメチル）ピリジン－４－イル）－１ｈ－ピラゾール－４－カルボキサミド）を使用して状態を治療する方法
BR112023017648A2 (pt) 2021-03-03 2023-11-14 Janssen Pharmaceutica Nv Terapia de combinação com o uso de um inibidor de malt1 e um inibidor de btk
AU2022326183A1 (en) * 2021-08-09 2024-03-28 Janssen Pharmaceutica Nv Compositions for use in treating b-cell malignancies

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2004625B1 (en) * 2006-03-22 2009-12-30 Vertex Pharmaceuticals Incorporated C-met protein kinase inhibitors for the treatment of proliferative disorders
WO2011036885A1 (ja) * 2009-09-25 2011-03-31 武田薬品工業株式会社 複素環化合物
KR20150020228A (ko) * 2012-05-31 2015-02-25 에프. 호프만-라 로슈 아게 아미노퀴나졸린 및 피리도피리미딘 유도체
US10835524B2 (en) * 2015-06-24 2020-11-17 University Of Florida Research Foundation, Incorporated Compositions for the treatment of pancreatic cancer and uses thereof
TWI795381B (zh) * 2016-12-21 2023-03-11 比利時商健生藥品公司 作為ｍａｌｔ１抑制劑之吡唑衍生物

Also Published As

Publication number Publication date
EP3927696C0 (en) 2023-10-18
MX2021010133A (es) 2021-09-23
AU2020226723A1 (en) 2021-08-19
MA55019A (fr) 2021-12-29
BR112021016400A2 (pt) 2021-10-13
EP3927696A1 (en) 2021-12-29
SG11202108909SA (en) 2021-09-29
ECSP21067828A (es) 2021-11-18
CA3129623A1 (en) 2020-08-27
KR20210131371A (ko) 2021-11-02
JOP20210227A1 (ar) 2023-01-30
WO2020169736A1 (en) 2020-08-27
IL285675A (en) 2021-10-31
JP2022523368A (ja) 2022-04-22
CN113474339A (zh) 2021-10-01
US20220127249A1 (en) 2022-04-28
UY38592A (es) 2020-08-31
EP3927696B1 (en) 2023-10-18
TW202045495A (zh) 2020-12-16
ES2966132T3 (es) 2024-04-18
EA202192320A1 (ru) 2021-11-16

Similar Documents

Publication Publication Date Title
PE20212067A1 (es) Forma cristalina de 1-(1-oxo-1,2-dihidroisoquinolin-5-il)-5-(trifluorometil)-n-(2- (trifluorometil)piridin-4-il)-1h-pirazol-4-carboxamida monohidratada
PH12019501707A1 (en) N-[4-fluoro-5-[[(2s,4s)-2-methyl-4-[(5-methyl-1,2,4-oxadiazol-3-yl)methoxy]-1-piperidyl]methyl]thiazol-2-yl]acetamide as oga inhibitor
MX2021013817A (es) Nuevas formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinop iridin-4-il)-4-metilfenil)-2-(trifluorometil)isonicotinamida como inhibidores de raf para el tratamiento del cancer.
EA201791955A1 (ru) ИНГИБИТОРЫ TGF-β
CL2017000469A1 (es) Derivados de tetrahidronaftaleno que inhiben la proteina mcl-1
NI201600098A (es) Composiciones farmacéuticas que comprenden azd9291
NZ627750A (en) Carbamate compounds and of making and using same
CL2019003619A1 (es) Preparación sólida para administración oral.
AR120703A1 (es) Formas sólidas de sal de 1,3-dihidroxi-2-(hidroximetil)propan-2-amina de ácido 2-((4-((s)-2-(5-cloropiridin-2-il)-2-metilbenzo[d][1,3]dioxol-4-il)piperidin-1-il)metil)-1-(((s)-oxetan-2-il)metil)-1h-benzo[d]imidazol-6-carboxílico
EA200971069A1 (ru) Метаболиты производных (тио)карбомоилциклогексана
MX2020001531A (es) Nuevos compuestos hetorociclicos como inhibidores de cdk8/19.
RU2019105794A (ru) Кристаллогидрат соединения (2s, 3r) -изопропил 2 - (((2- (1,5-диметил-6-оксо-1,6-дигидропиридин-3-ил) -1 - ((тетрагидро-2h-пиран) -4-ил) метил) -1h-бензо [d] имидазол-5-ил) метил) амино) -3-гидроксибутаноат эдисилат
CL2021001629A1 (es) Compuestos de halo-alilamina y uso de los mismos
MX2021003945A (es) Compuestos de indolinona para uso como inhibidores de map4k1.
AR119318A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
WO2020247298A3 (en) 1-pyrazolyl, 5-, 6- disubstituted indazole derivatives as lrrk2 inhibitors, pharmaceutical compositions, and uses thereof
EA202190586A1 (ru) N-замещенные диоксоциклобутениламино-3-гидроксипиколинамиды, приемлемые в качестве ингибиторов ccr6
RU2016136351A (ru) Пиррол-замещенное производное индолона, способ его получения, включающая его композиция и применение
MX2019015431A (es) Compuesto cíclico tipo cumarina como inhibidor de mek y su uso.
MA38697A1 (fr) 4-(5-(4-chlorophényl)-2-(2-cyclopropylacétyl)-1,4-diméthyl-1h-pyrrol-3-yl)benzène-sulfonamide à titre de modulateur du nachr alpha 7
BR112016013974A8 (pt) composto, composição farmacêutica e uso de um composto.
BRPI0413500A (pt) compostos, processos para a sua preparação, composição farmacêutica que compreende os mesmos, utilização de um composto, métodos para o tratamento e profilaxia de artrite, diabetes, distúrbios alimentares e obesidade
EA202190452A1 (ru) Ингибиторы cdk8/19
EA202090241A1 (ru) Новые гетероциклические соединения как ингибиторы cdk8/19
PL425832A1 (pl) Genisteina oraz jej kompozycja do zastosowania w leczeniu choroby Alzheimera